{"entity":{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","aka":["Treadwell Therapeutics, Inc"],"tldr":"Treadwell Therapeutics is a Hong Kong-based biotechnology company running 3 late-stage cancer trials of CFI-402411, CFI-400945 and CFI-402257 in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer.","summary":"Treadwell Therapeutics, based in Hong Kong, Hong Kong, is a biotechnology company. Treadwell Therapeutics is a clinical-stage, multi-modality oncology company developing small molecules, biologics and T-cell receptor therapies against novel cancer targets. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CFI-402411, CFI-400945 and CFI-402257 in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer. The largest, NCT04521413 (Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies), plans to enrol 170 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://treadwelltx.com"},{"label":"ClinicalTrials.gov: trials led by Treadwell Therapeutics","url":"https://clinicaltrials.gov/search?lead=Treadwell%20Therapeutics%2C%20Inc"},{"label":"Pipeline page","url":"https://treadwelltx.com/pipeline/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","mds","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04730258","nct04521413","nct05251714"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hong Kong","country":"HK","companyType":"biotech","website":"https://treadwelltx.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/treadwell-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"trial":[{"id":"nct04730258","kind":"trial","name":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML","route":"/trials/nct04730258/"},{"id":"nct05251714","kind":"trial","name":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","route":"/trials/nct05251714/"},{"id":"nct04521413","kind":"trial","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","route":"/trials/nct04521413/"}]}}